Bal Pharma Ltd
Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Bal Pharma Ltd
BALPHARMA
Price Chart
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Insufficient Data
Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Key Metrics
Forecast & RatingsDetailed Forecast
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Gland Pharma Ltd
Cadila Healthcare Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Increased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 2.39%
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Bal Pharma reports consolidated net profit of Rs 3.58 crore in the March 2021 quarter
3 weeks ago•Business Standard
Bal Pharma reports standalone net profit of Rs 4.38 crore in the March 2021 quarter
3 weeks ago•Business Standard
Recent EventsAll events
Reply to Clarification- Financial results
The Exchange had sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is enclosed. | Download
The Exchange had sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is enclosed. | Download
Related Party Transactions
Cash Dividend
Final • Div/Share: ₹ 1
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Insufficient Data